tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Theriva Biologics Secures $4M Through Warrant Agreement

Story Highlights
Theriva Biologics Secures $4M Through Warrant Agreement

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Theriva Biologics ( (TOVX) ) has shared an update.

On October 16, 2025, Theriva Biologics entered into a warrant inducement agreement with existing institutional investors, resulting in the exercise of warrants to purchase up to 7,360,460 shares of common stock at a reduced price, generating approximately $4.0 million in gross proceeds. The company issued new warrants for additional shares, set to be exercisable upon stockholder approval, with the proceeds intended for working capital and corporate purposes. This transaction, advised by A.G.P./Alliance Global Partners, is expected to impact Theriva’s operational liquidity and strategic positioning in the biotech industry.

The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics, Inc. is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, particularly in areas with high unmet needs. The company is advancing a new oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery, aiming to enhance tumor cell death and improve the efficacy of co-administered cancer therapies. Theriva’s lead candidates include VCN-01, SYN-004, and SYN-020, targeting various cancer-related and gastrointestinal conditions.

Average Trading Volume: 4,511,539

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.14M

Learn more about TOVX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1